HP
MRTX

Hikari Power’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Hikari Power’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$365K – 99
2017
Q2 		$365K Buy
+100,000
New +$383K 0.05% 69

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hikari Power's MRTX Position: Q3 2017 in Review

Hikari Power sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2017, closing a stake of 100,000 shares — an estimated $365K sold.

Hikari Power first reported a position in MRTX in Q2 2017 and held it in 1 quarter. The position peaked at $365K in Q2 2017. 49 funds tracked by Wall St. Rank hold MRTX as of Q3 2017.

  • Hikari Power reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Hikari Power sold 100,000 Mirati Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $365K.
  • Hikari Power first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Hikari Power's Mirati Therapeutics, Inc. Common Stock position peaked at $365K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Hikari Power's 13F filing for Q3 2017, filed 8 Nov 2017.